3/23
11:02 am
huma
Wall Street Analysts Think Humacyte, Inc. (HUMA) Is a Good Investment: Is It? [Yahoo! Finance]
Medium
Report
Wall Street Analysts Think Humacyte, Inc. (HUMA) Is a Good Investment: Is It? [Yahoo! Finance]
3/23
08:00 am
huma
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026
Medium
Report
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026
3/20
08:22 am
huma
Humacyte, Inc. (HUMA) Submits Marketing Authorization Application in Israel for Symvess [Yahoo! Finance]
Low
Report
Humacyte, Inc. (HUMA) Submits Marketing Authorization Application in Israel for Symvess [Yahoo! Finance]
3/19
08:31 am
huma
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia
High
Report
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia
3/19
08:30 am
huma
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
High
Report
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
3/17
08:43 am
huma
Humacyte (HUMA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Humacyte (HUMA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.
3/17
08:29 am
huma
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair [Yahoo! Finance]
Low
Report
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair [Yahoo! Finance]
3/17
08:00 am
huma
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair
Low
Report
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair
3/10
03:03 pm
huma
Humacyte, Inc. (HUMA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Humacyte, Inc. (HUMA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/6
03:57 pm
huma
Humacyte, Inc. (HUMA) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Neutral
Report
Humacyte, Inc. (HUMA) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
3/2
08:28 am
huma
Humacyte To Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Humacyte To Participate in Upcoming Investor Conferences [Yahoo! Finance]
3/2
08:00 am
huma
Humacyte To Participate in Upcoming Investor Conferences
Low
Report
Humacyte To Participate in Upcoming Investor Conferences
2/19
08:23 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
2/18
08:00 am
huma
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
Low
Report
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
2/18
03:27 am
huma
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Symvess Battlefield Trauma Potential [Yahoo! Finance]
Medium
Report
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Symvess Battlefield Trauma Potential [Yahoo! Finance]
2/9
06:09 pm
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at BTIG Research.
High
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at BTIG Research.
2/9
05:10 pm
huma
Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist [Seeking Alpha]
High
Report
Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist [Seeking Alpha]
2/9
02:45 pm
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Low
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
2/9
08:00 am
huma
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
High
Report
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
1/21
10:38 am
huma
Humacyte (NASDAQ:HUMA) had its price target lowered by analysts at Benchmark Co. from $11.00 to $10.00. They now have a "buy" rating on the stock.
Medium
Report
Humacyte (NASDAQ:HUMA) had its price target lowered by analysts at Benchmark Co. from $11.00 to $10.00. They now have a "buy" rating on the stock.
1/8
08:00 am
huma
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
Medium
Report
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
1/7
11:58 am
huma
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Low
Report
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
1/5
08:42 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
1/5
08:06 am
huma
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel [Yahoo! Finance]
Medium
Report
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel [Yahoo! Finance]
1/5
08:00 am
huma
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
Medium
Report
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel